Compare · CCCC vs KYMR
CCCC vs KYMR
Side-by-side comparison of C4 Therapeutics Inc. (CCCC) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCCC and KYMR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- KYMR is the larger of the two at $9.58B, about 19.7x CCCC ($486.5M).
- Over the past year, CCCC is up 191.1% and KYMR is up 154.6% - CCCC leads by 36.4 points.
- KYMR has been more active in the news (37 items in the past 4 weeks vs 4 for CCCC).
- KYMR has more recent analyst coverage (25 ratings vs 22 for CCCC).
- Company
- C4 Therapeutics Inc.
- Kymera Therapeutics Inc.
- Price
- $4.39+3.41%
- $116.31+16.42%
- Market cap
- $486.5M
- $9.58B
- 1M return
- +25.21%
- +44.02%
- 1Y return
- +191.06%
- +154.65%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 4
- 37
- Recent ratings
- 22
- 25
C4 Therapeutics Inc.
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest CCCC
- C4 Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- C4 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
- Director Anderson Kenneth Carl exercised 1,070 shares at a strike of $2.11, increasing direct ownership by 2% to 69,300 units (SEC Form 4)
- C4 Therapeutics to Participate in Upcoming Conferences
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by C4 Therapeutics Inc.
- C4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Latest KYMR
- SEC Form 4 filed by Director Bvf Partners L P/Il
- SEC Form 4 filed by Director Booth Bruce
- Chief Business Officer Goodman Noah exercised 5,000 shares at a strike of $21.05 and sold $570,000 worth of shares (5,000 units at $114.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Director Albers Jeffrey W.
- SEC Form 4 filed by Director Hrustanovic Gorjan
- SEC Form 4 filed by Director Esposito Pamela
- SEC Form 4 filed by Director Maraganore John
- SEC Form 4 filed by Director Sandor Victor
- SEC Form 4 filed by Director Ridloff Elena
- SEC Form 144 filed by Kymera Therapeutics Inc.